Craig305
3 meses hace
Nationwide - August 28, 2024 (USANews.com) - ADM Tronics Unlimited, Inc. (OTCQB: ADMT), a publicly traded, FDA-registered medical device company known for its innovative approach to non-invasive therapeutic technologies, has introduced the Vet-Sonotron®, a groundbreaking veterinary therapy device. Designed to provide effective pain relief in animals without the use of drugs, Vet-Sonotron® addresses a broad spectrum of musculoskeletal conditions in small animals and horses, offering veterinarians a safe and efficient solution for managing pain in their patients.
A Technological Breakthrough in Veterinary Care
Vet-Sonotron® represents a significant advancement in veterinary medicine, developed specifically to alleviate pain in animals suffering from conditions such as osteoarthritis, hip dysplasia, tendon problems, navicular syndrome and a wide number of other musculoskeletal issues. This device is non-invasive, meaning it requires no surgery or injections, and works without the side effects commonly associated with pharmaceutical pain treatments. The technology operates by emitting a unique energy signal that interacts with the animal’s tissues, promoting pain relief and supporting the body's natural healing processes. This makes Vet-Sonotron® an ideal option for veterinarians seeking to enhance the quality of care they provide, particularly for animals that may not respond well to traditional pain medications.
Backed by ADM Tronics’ Expertise
The development and production of Vet-Sonotron® are a testament to ADM Tronics' extensive experience and dedication to advancing medical technology. With a history of pioneering therapeutic devices, ADM Tronics has established itself as a leader in the creation of non-invasive treatment options for both veterinary and human applications. The company's expertise is reflected in the Vet-Sonotron’s design and functionality, which prioritize both efficacy and safety.
ADM Tronics has been at the forefront of medical innovation for years, and the Vet-Sonotron® is the latest in a line of products that leverage cutting-edge technology to improve patient outcomes. The device is now in production and is being marketed to veterinarians across the United States, offering a new tool for managing pain in small animals and horses. The convenience of using the Vet-Sonotron® in veterinary offices, clinics, and even in the field further enhances its appeal, making it a versatile option for a variety of veterinary settings.
Non-Invasive, Drug-Free, and Effective
One of the key differentiators of Vet-Sonotron® is its non-invasive nature. Unlike other pain management methods that may require drugs or invasive procedures, Vet-Sonotron® offers a solution that avoids the risks associated with these approaches. By providing pain relief without drugs, the device eliminates the potential for side effects, making it a safer option for animals, especially those with sensitivities to medication or underlying health conditions that make drug treatment problematic.
Furthermore, the ease of use and portability of the Vet-Sonotron® allows veterinarians to administer treatment quickly and effectively, reducing the stress and discomfort often associated with pain management procedures. This aspect is particularly important in veterinary medicine, where minimizing the animal's distress is a priority.
A Glimpse into the Future of Pain Management
ADM Tronics is not only revolutionizing veterinary care but is also setting the stage for future advancements in human medicine. The company is actively developing a medical version of the Vet-Sonotron® technology, aimed at providing non-invasive pain relief for humans. This forthcoming device is intended to be submitted for FDA clearance through a 510(k) application, demonstrating ADM Tronics’ commitment to expanding the reach of its innovative technologies.
The ongoing development of a human medical version of this technology underscores ADM Tronics' vision of providing safe, effective, and non-invasive treatment options for pain management across both animal and human healthcare sectors. The successful application of this technology in veterinary medicine offers promising insights into its potential for human use, positioning ADM Tronics as a key player in the future of pain management.
An Invitation to Learn More
Veterinarians interested in incorporating this cutting-edge technology into their practice can now access the Vet-Sonotron®, which is available for purchase or lease. ADM Tronics invites professionals and the broader community to explore the benefits of this innovative device.
For more information on Vet-Sonotron® and ADM Tronics’ other technologies, please visit www.admtronics.com and www.vet-sonotron.com. To see Vet-Sonotron in action, watch this demonstration video.
For further inquiries, contact Andre DiMino, President of ADM Tronics, at +1-201-767-6040 or via email at sales@admtronics.com.
Sonotron® is a registered trademark of ADM Tronics Unlimited, Inc.
Craig305
8 meses hace
ADM Tronics to Host Shareholder Video Call on March 27 to Update Launch and Significance of Vet-Sonotron Veterinary Pain Treatment Device
NORTHVALE, NJ / ACCESSWIRE / March 20, 2024 / ADM Tronics (OTCQB:ADMT), an innovator of electronic medical device technologies, invites shareholders to a shareholder video call on March 27, 2024 at 2 PM Eastern, where shareholders will be updated about ADMT's new proprietary Vet-Sonotron®, non-invasive veterinary therapeutic technology. The Vet-Sonotron has demonstrated positive efficacy in treating pain and inflammation, without drugs nor adverse side effects, and is now in initial commercialization for pets and other animals, including horses.
Based on the positive therapeutic results demonstrated by the Vet-Sonotron, ADMT is in development of a human medical version - the Sonotron. When development is completed, ADMT intends to submit a 510(k) to the FDA for the Sonotron for use in the treatment of chronic and acute musculoskeletal pain conditions in humans. The non-invasive therapy delivered by the Sonotron has no known side effects and may be an effective option to pain drugs that have potential negative side effects and dependencies. Management believes the Sonotron technology has the potential to impact shareholder valuations significantly should FDA clearance be secured.
The shareholder video call will be held March 27, 2024 at 2:00 PM Eastern Daylight Time.
Register in advance for this meeting:
https://us06web.zoom.us/meeting/register/tZcsd-qgqjguG93zMFc_rH4IEpdDYQ2NWjEl
After registering, you will receive a confirmation email containing information about joining the meeting.
For more information about the Vet-Sonotron visit www.vet-sonotron.com.
ADMT welcomes inquiries for its medical device contract engineering and manufacturing services at www.admteng.com.
About ADMT
ADMT is a diversified, technology-based developer and manufacturer of innovative technologies and products. ADMT has three areas of activity: Proprietary Electronic Medical Devices; Engineering, Regulatory and Manufacturing Services; and, Eco-Friendly, Water-Based Formulations. The Company's headquarters, laboratories, and FDA-Registered medical device manufacturing operations are in Northvale, NJ. ADMT's multi-disciplinary team of engineers, researchers and technologists utilize advanced technology infrastructure, for research, development and commercialization of diversified technologies. Visit www.admtronics.com.
Sonotron® is a registered trademark of ADM Tronics Unlimited, Inc.
Investor Relations:
Howard Isaacs 562-987-4939 HISAACS@EARTHLINK.NET
Richard Cavalli 303-956-1777 RICHARDACAVALLI@GMAIL.COM
bb72mo
1 año hace
I emailed Andre yesterday and this was his response.
In the release there was the description of using resources towards the Vet-Sonotron development. With the delays we had from the supply chain problems we experienced, the strategy was to make a strong push to get the technology into production. That diverted resources away from customer projects and production - resulting in reduced revenues. We are not pleased with the reduced revenues, but we want to get our own device completed and commercialized to have the company realize the significantly higher margins than we can achieve from contract manufacturing of customer products.
So, I know it is very disappointing to have these numbers, but I am hopeful and firmly believe our strategy is best for the growth and profitability of the company.
Thanks.
Kind regards,
Andre’
bb72mo
1 año hace
Dear ADM Tronics Shareholder:
I want to thank you, and every one of our shareholders, for your loyalty and your belief in ADM Tronics. Your investment has allowed us to be laser-focused on building a robust pipeline of products and has allowed us to develop what we believe to be our game-changing Sonotron® technology to treat pain. We are planning to commercially launch the Vet-Sonotron® - for pets and animals - and later, The Sonotron® for human medical applications. We have a major financial and time investment in the development of this technology that we believe will reward ADMT with significant revenues and profits.
We are especially proud that our Sonotron technology has demonstrated a giant leap in treating pain without the use of drugs or opioids. I invite you to watch this short video demonstrating the Vet-Sonotron's pain relief and visible inflammation reduction for a racehorse that was suffering an acute painful injury during a race.
The demand for solutions to treat pain for both animals and humans is very large. American pet owners will spend about $2 billion in 2023 for pain management for their pets. The National Academy of Sciences estimated in 2010 that more than 100 million American individuals experienced chronic unrelieved pain. The estimated cost was $560 billion to $635 billion per year, composed of direct health care costs of between $261 billion to $300 billion.
Our Sonotron device demonstrates unprecedented pain relief that is non-invasive and has no known adverse side effects. Over the decades, I have witnessed many different devices for treating pain, including drugs and opioids, but have never seen anything that works this well, this fast, with long-lasting results, and with no known adverse side effects. This is truly an exceptionally effective pain treating device that we believe has the potential to become a widespread solution for treating pain without drugs for both animals and for humans.
We have good reason to believe the veterinary market will be receptive to the Vet-Sonotron. We plan to offer the device for purchase or on a pay-per-use basis we have developed. This is a remote cloud-based metering system that allows a veterinary practitioner to be charged for treatment units delivered by the Vet-Sonotron. Our market testing has indicated that potential users prefer this, by far, as opposed to purchase. At the same time, it gives our company an ongoing revenue source - a truly win-win arrangement. We feel that this model has the potential to generate large, high-margin revenues for ADM Tronics over many years to come.
ADM Tronics has been developing and taking medical devices through the FDA process for over 40 years and we believe we have a high probability of success for our human model of the Sonotron pain therapy device. In our testing, efficacy is exceptional; each treatment is long lasting; and there are no known adverse side effects.
With commercialization for animals imminent, and the possibility of expanding sales to humans in later 2024, we believe the impact to ADM Tronics' valuation can be substantial because there are fewer than 68 million shares outstanding which today represents a total market capitalization of about $6,800,000.
Another significant matter of interest to shareholders is that a prior and very good client plans to return to us for our engineering services for development and manufacturing of its' innovative medical technology to help people facing amputations due to diabetic foot ulcers and other non-healing wounds. This technology could be very meaningful for the many people suffering with debilitating chronic wounds. We believe this returning client with this new medical device can bring increasing and profitable revenues to our company in our Medical Device Engineering services segment. And once this new technology completes clinical studies and, should it receive the green light from the FDA, it can generate revenues and profits in our contract medical device manufacturing segment.
A few financial highlights for the Third Fiscal Quarter ended December 31, 2022: Your company has ample cash on hand to finance operations; the current ratio is over a healthy 2.5 to 1of current assets to current liabilities; the company reported very low debt; and, the company was profitable with $93,771 in profits for the reporting quarter, representing over 9% net profit. (Complete financial results are available in the Company's Quarterly Report on Form 10Q for December 31, 2022, available at www.sec.gov.)
I hope I have successfully conveyed to you why we are more optimistic than ever and look forward to an exciting and prosperous future with you. I want you to please feel free to call or email me if you have any questions.
I very much look forward to our next Letter to Shareholders.
Thank you and regards,
s/s Andre’ DiMino
Andre' DiMino
President and CEO
Monitoree múltiples cotizaciones en tiempo real de los principales intercambios, como la Bolsa de Valores de Londres, NASDAQ, NYSE, AMEX, Bovespa y más.
Hot Features
Premium
